RS52082B - Oralni rastvor aripiprazola - Google Patents

Oralni rastvor aripiprazola

Info

Publication number
RS52082B
RS52082B YU84703A YUP84703A RS52082B RS 52082 B RS52082 B RS 52082B YU 84703 A YU84703 A YU 84703A YU P84703 A YUP84703 A YU P84703A RS 52082 B RS52082 B RS 52082B
Authority
RS
Serbia
Prior art keywords
oral solution
aripiprazole
acid
group
agents selected
Prior art date
Application number
YU84703A
Other languages
English (en)
Inventor
Prakash Parab
Joyce Chou
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23099862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52082(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of YU84703A publication Critical patent/YU84703A/sh
Publication of RS52082B publication Critical patent/RS52082B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Farmaceutski rastvor pogodan za oralnu administraciju naznačen time što uključuje aripiprazol, neki farmaceutski pogodni sistem rastvarača koji se sastoji od vode i jednog ili više agenasa odabranih od grupe koja se sastoji od etanola, glicerina, propilen glikola i sorbitola, jednog ili više sredstava za poboljšanje i/ili za maskiranje ukusa, i jednog ili više agenasa odabranih od grupe koja uključuje mlečnu kiselinu, sirćetnu kiselinu, vinsku kiselinu i limunsku kiselinu, pri čemu je pH navedenog rastvora između 2,5 i 4,5.Prijava sadrži još 13 patentnih zahteva.
YU84703A 2001-04-25 2002-04-24 Oralni rastvor aripiprazola RS52082B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28671801P 2001-04-25 2001-04-25

Publications (2)

Publication Number Publication Date
YU84703A YU84703A (sh) 2006-08-17
RS52082B true RS52082B (sr) 2012-06-30

Family

ID=23099862

Family Applications (1)

Application Number Title Priority Date Filing Date
YU84703A RS52082B (sr) 2001-04-25 2002-04-24 Oralni rastvor aripiprazola

Country Status (37)

Country Link
US (1) US6977257B2 (sr)
EP (2) EP2436384B2 (sr)
JP (1) JP4401077B2 (sr)
KR (1) KR100909329B1 (sr)
CN (1) CN1512884B (sr)
AR (1) AR033168A1 (sr)
AT (1) ATE537831T1 (sr)
AU (1) AU2002254722B2 (sr)
BG (1) BG66177B1 (sr)
BR (1) BR0208986A (sr)
CA (1) CA2445276C (sr)
CY (1) CY1112606T1 (sr)
CZ (1) CZ306181B6 (sr)
DK (1) DK1381367T3 (sr)
EE (1) EE05581B1 (sr)
ES (1) ES2377855T3 (sr)
GE (1) GEP20053602B (sr)
HK (2) HK1058316A1 (sr)
HR (1) HRP20030870B1 (sr)
HU (1) HU230456B1 (sr)
IL (2) IL158202A0 (sr)
IS (1) IS2863B (sr)
MX (1) MXPA03009728A (sr)
MY (1) MY129350A (sr)
NO (1) NO324606B1 (sr)
NZ (1) NZ528550A (sr)
PE (1) PE20021086A1 (sr)
PL (1) PL206882B1 (sr)
PT (1) PT1381367E (sr)
RS (1) RS52082B (sr)
RU (1) RU2295960C2 (sr)
SK (1) SK287948B6 (sr)
TW (1) TWI337865B (sr)
UA (1) UA76144C2 (sr)
UY (1) UY27273A1 (sr)
WO (1) WO2002085366A1 (sr)
ZA (1) ZA200307797B (sr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
DE60327225D1 (de) * 2002-08-20 2009-05-28 Bristol Myers Squibb Co Aripiprazol-komplex-formulierung und verfahren
CN1867359B (zh) * 2003-10-08 2010-12-15 马林克罗特公司 哌甲酯溶液及其制药用途和制备方法
JP4836797B2 (ja) * 2003-10-23 2011-12-14 大塚製薬株式会社 放出制御性無菌注射アリピプラゾール製剤および方法
CA2552988A1 (en) * 2004-01-21 2005-08-04 Janssen Pharmaceutica Nv Mitratapide oral solution
JP2009508859A (ja) 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
US8865722B2 (en) * 2006-01-05 2014-10-21 Teva Pharmaceutical Industries Ltd. Wet formulations of aripiprazole
CN101351193A (zh) * 2006-01-05 2009-01-21 特瓦制药工业有限公司 阿立哌唑的干法制剂
JP4892264B2 (ja) * 2006-03-30 2012-03-07 高田製薬株式会社 リスペリドン水性液剤
ATE523602T1 (de) 2006-06-12 2011-09-15 Hadasit Med Res Service Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
DK2170279T3 (en) * 2007-07-31 2018-03-12 Otsuka Pharma Co Ltd PROCEDURES FOR PREPARING AN ARIPIPRAZOL SUSPENSION AND A FREEZER DRIED FORMULATION
WO2009042166A1 (en) * 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
WO2010146872A1 (ja) * 2009-06-19 2010-12-23 株式会社メドレックス アリピプラゾールと有機酸を有効成分とする外用剤組成物
TR201000948A1 (tr) 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
EP2609923B1 (en) 2010-03-31 2017-05-24 Gilead Pharmasset LLC Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
HUE065359T2 (hu) 2011-03-18 2024-05-28 Alkermes Pharma Ireland Ltd Szorbitán-észtereket tartalmazó gyógyászati készítmények
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102846616B (zh) * 2011-06-27 2015-05-06 上海中西制药有限公司 一种阿立哌唑制剂及其制备方法
US9241876B2 (en) 2011-06-27 2016-01-26 Shanghai Zhongxi Pharmaceutical Corporation Aripiprazole medicament formulation and preparation method therefor
TWI632921B (zh) * 2011-10-19 2018-08-21 大塚製藥股份有限公司 口服溶液
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
CA2867123C (en) 2012-03-19 2021-02-16 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US20150174247A1 (en) * 2012-06-29 2015-06-25 Maruishi Pharmaceutical Co., Ltd. Oral pharmaceutical preparation of aripiprazole
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
KR101571670B1 (ko) 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9452134B2 (en) * 2012-09-26 2016-09-27 Bristol-Myers Squibb Company Apixaban solution formulations
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US20140107130A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals, LLC Oral Solution Formulations of Aripiprazole
PL2908859T3 (pl) * 2012-10-16 2017-10-31 Arven Ilac Sanayi Ve Ticaret As Formulacje arypiprazolu
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
CN103393594A (zh) * 2013-08-22 2013-11-20 万特制药(海南)有限公司 一种新的阿立哌唑的制剂组合物
CN110368360A (zh) 2014-03-20 2019-10-25 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
WO2016189504A1 (en) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Non-lyophilized compositions of aripiprazole and methods of preparation thereof
JP6039849B1 (ja) * 2015-06-12 2016-12-07 高田製薬株式会社 アリピプラゾール含有内用液剤
WO2017025930A1 (en) * 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
CN108434146A (zh) * 2017-02-16 2018-08-24 天津国际生物医药联合研究院 一种hiv-1整合酶抑制剂的溶液剂及其制备方法和应用
CN109498556A (zh) * 2017-09-15 2019-03-22 万特制药(海南)有限公司 阿立哌唑口服溶液及其制备方法
CN112423754A (zh) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 阿立哌唑的给药策略
CN112666267B (zh) * 2019-10-15 2023-09-26 上海上药中西制药有限公司 一种阿立哌唑药品有关物质的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU843739A3 (ru) 1978-02-17 1981-06-30 Карл Томэ Гмбх (Фирма) Способ получени карбостириловыхили ОКСиНдОлОВыХ пРОизВОдНыХ
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS5959663A (ja) 1982-09-29 1984-04-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体−シクロデキストリン包接化合物
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5457099A (en) 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
TW254855B (sr) * 1993-07-28 1995-08-21 Otsuka Pharma Co Ltd
WO1998043673A1 (en) * 1997-03-31 1998-10-08 Johnson & Johnson Consumer Companies, Inc. Solvent system for enhanced penetration of pharmaceutical compounds
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
JP2002524397A (ja) * 1998-09-03 2002-08-06 アルサイド コーポレーション 耐凍結性の局所用殺菌剤及びそれに関連する方法
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation

Also Published As

Publication number Publication date
UA76144C2 (uk) 2006-07-17
HU230456B1 (hu) 2016-07-28
HRP20030870B1 (en) 2011-10-31
KR100909329B1 (ko) 2009-07-24
DK1381367T3 (da) 2012-04-10
AR033168A1 (es) 2003-12-03
US20020193438A1 (en) 2002-12-19
HRP20030870A2 (en) 2004-06-30
CA2445276C (en) 2009-10-13
EP2436384A2 (en) 2012-04-04
EE200300523A (et) 2004-02-16
UY27273A1 (es) 2002-11-29
HUP0303946A3 (en) 2005-06-28
EP2436384A3 (en) 2012-09-19
BR0208986A (pt) 2004-04-20
ATE537831T1 (de) 2012-01-15
BG108216A (bg) 2004-12-30
BG66177B1 (bg) 2011-11-30
HK1058316A1 (en) 2004-05-14
PE20021086A1 (es) 2002-12-14
CY1112606T1 (el) 2016-02-10
RU2003132426A (ru) 2005-04-20
CZ306181B6 (cs) 2016-09-14
GEP20053602B (en) 2005-08-10
IS2863B (is) 2013-12-15
NO20034705D0 (no) 2003-10-21
MY129350A (en) 2007-03-30
CN1512884A (zh) 2004-07-14
ES2377855T3 (es) 2012-04-02
NO20034705L (no) 2003-11-28
IS6994A (is) 2003-10-14
TWI337865B (en) 2011-03-01
WO2002085366A1 (en) 2002-10-31
JP2004532225A (ja) 2004-10-21
CZ20032821A3 (cs) 2004-09-15
CN1512884B (zh) 2010-05-26
IL158202A (en) 2008-04-13
PL364666A1 (en) 2004-12-13
HK1168792A1 (en) 2013-01-11
HUP0303946A2 (hu) 2004-04-28
ZA200307797B (en) 2004-10-06
EP1381367B1 (en) 2011-12-21
SK287948B6 (sk) 2012-06-04
CA2445276A1 (en) 2002-10-31
EP1381367A1 (en) 2004-01-21
PT1381367E (pt) 2012-03-01
YU84703A (sh) 2006-08-17
JP4401077B2 (ja) 2010-01-20
EP2436384B2 (en) 2018-05-23
AU2002254722B2 (en) 2006-11-09
IL158202A0 (en) 2004-05-12
SK12642003A3 (sk) 2004-07-07
EP1381367A4 (en) 2009-07-01
KR20030096332A (ko) 2003-12-24
EP2436384B1 (en) 2015-06-10
RU2295960C2 (ru) 2007-03-27
NZ528550A (en) 2005-03-24
MXPA03009728A (es) 2004-01-29
NO324606B1 (no) 2007-11-26
PL206882B1 (pl) 2010-10-29
EE05581B1 (et) 2012-10-15
US6977257B2 (en) 2005-12-20

Similar Documents

Publication Publication Date Title
RS52082B (sr) Oralni rastvor aripiprazola
FR2836915B1 (fr) Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
AU2001230892A1 (en) Orally administered pharmaceutical formulations of benzimidazole derivatives andthe method of preparing the same
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
EP1246608A4 (en) PHARMACEUTICAL PREPARATIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES WITH LOW WATER SOLUBILITY
NO20020976L (no) Retarderte, orale, farmasöytiske administreringsformer
NO961136L (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
RS50360B (sr) Farmaceutske formulacije derivata platine
FR2862647B1 (fr) Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
PT1556371E (pt) Derivados de benzimidazole e sua utilizacao como pro-farmacos de inibadores da bomba de protoes.
DE60019334D1 (de) Antivirale arznei
DE60239752D1 (de) Den geschmack verdeckende auslaufsichere formulierung
RS50445B (sr) Farmaceutski rastvori levosimendana
NO20010863L (no) Nye orale formuleringer for 5-HT4-agonister eller - antagonister
HRP20090022T3 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
DK1957037T3 (da) Farmaceutisk præparat til nasal anvendelse af fentanyl
HUP0500842A2 (hu) Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
DE60131416D1 (de) Chirale fluorochinolizinon arginine salze
EP1507764A4 (en) NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS THEREOF
SE0001916D0 (sv) Novel formulation
DE69927997D1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
YU87501A (sh) Farmaceutski kompleksi
CO4930262A1 (es) Producto farmaceutico cristalino, su preparacion y uso como sustancia terapeutica
DE60029979D1 (de) LIPOSOMZUSAMMENSETZUNG VON 6,9-BIS-i(2-AMINOETHYL)-AMINOöBENZOiGöISOQUINOLIN-5,10-DIONE-DIMALEAT